HIGHLIGHTS
- who: G. Lopez-Vivanco from the Trastuzumab Trastuzumab Time and motion SpainCórdoba (IMIBIC), Universidad de Córdoba, Hospital Reina have published the research: Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain, in the Journal: (JOURNAL)
- what: The aims of this study were: to estimate the HCP time invested in the preparation and administration of trastuzumab IV and SC, patient infusion chair time, patient treatment room time, and patient hospital time according to the route of administration and_(2) to estimate the direct costs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.